Semaglutide , - Glucagon-like peptide-1
2026: Knudsen E, Tadje J, Coggins C, Venketaraman V
These complaints may have various causes, including changes related to weight loss itself, increased physical activity, or other underlying conditions rather than direct drug effects
Our dedicated practitioners are highly trained and experienced in solving the issues associated with hormonal imbalance
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 16 GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway Authors Xiang J , Qin L , Zhong J, Xia N , Liang Y Received 12 June 2023 Accepted for publication 5 August 2023 Published 15 August 2023 Volume 2023:16 Pages 24332446 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Konstantinos Tziomalos Jie Xiang, 1 Liyan Qin, 2 Jinling Zhong, 3 Ning Xia, 2 Yuzhen Liang 3 1 Department of Clinical Nutrition, The First Affiliated Hospital of Guangxi Medical University, Nanning, Peoples Republic of China
doi:10.1016/j.cell.2007.06.009